/CLLS
CLLS Stock - Cellectis S.A.
Healthcare|BiotechnologyNASDAQ
$4.37+5.05%
+$0.21 (+5.05%) • Dec 19
68
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.90
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.0
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+37.3%upside
Target: $6.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for CLLS
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$4.33 – $4.41
TARGET (TP)$6.00
STOP LOSS$4.02
RISK/REWARD1:4.7
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta3.04
52W High$5.48
52W Low$1.10
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $41.51M | $755,000 | $19.17M | $30.35M | $51.06M |
| Gross Profit | $32.32M | $-6,664,000 | $10.69M | $28.50M | $49.11M |
| Gross Margin | 77.9% | -882.6% | 55.7% | 93.9% | 96.2% |
| Operating Income | $-59,554,000 | $-97,302,000 | $-89,666,000 | $-103,481,000 | $-42,311,000 |
| Net Income | $-36,761,000 | $-101,059,000 | $-106,139,000 | $-114,197,000 | $-81,074,000 |
| Net Margin | -88.6% | -13385.3% | -553.6% | -376.3% | -158.8% |
| EPS | $-0.41 | $-1.77 | $-2.33 | $-1.93 | $-1.71 |
Company Overview
Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma; ALLO-316 for the treatment of Renal Cell Carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART22 to treat B-cell acute lymphoblastic leukemia. It is also developing UCARTCS1 and ALLO-715 for the treatment of multiple myeloma. The company has strategic alliances with Allogene Therapeutics, Inc.; Les Laboratoires Servier; The University of Texas M.D. Anderson Cancer Center; and Iovance Biotherapeutics, as well as a strategic research and development collaboration with Cytovia Therapeutics, Inc. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
2
100%
Hold / Neutral
0%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
2 Bullish0 Neutral/Bearish
Price Targets
$8
Average Target
↑ 83.1% Upside
Now
$6
Low
$8
Average
$10
High
Based on 2 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| March 17th 2023 | Bryan Garnier | Initiation | Buy | $6 |
| May 18th 2022 | Robert W. Baird | Upgrade | Outperform | $10 |
Earnings History & Surprises
CLLSBeat Rate
44%
Last 18 quarters
Avg Surprise
-35.8%
EPS vs Estimate
Beats / Misses
8/9
1 met exactly
Latest EPS
$0.01
Q4 2025
EPS Surprise History
Q1 24
-218.2%
$-0.70vs$-0.22
Q2 24
-93.9%
$-0.64vs$-0.33
Q3 24
+15.2%
$-0.28vs$-0.33
Q4 24
-15.0%
$-0.23vs$-0.20
Q1 25
-366.7%
$-0.16vs$0.06
Q2 25
+5.3%
$-0.18vs$-0.19
Q3 25
-140.0%
$-0.24vs$-0.10
Q4 25
+110.0%
$0.01vs$-0.10
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 11, 2026 | — | — | — | — |
Q1 2026 | Mar 11, 2026 | — | — | — | — |
Q4 2025 | Nov 7, 2025 | $-0.10 | $0.01 | +110.0% | ✓ BEAT |
Q3 2025 | Aug 4, 2025 | $-0.10 | $-0.24 | -140.0% | ✗ MISS |
Q2 2025 | May 12, 2025 | $-0.19 | $-0.18 | +5.3% | ✓ BEAT |
Q1 2025 | Mar 13, 2025 | $0.06 | $-0.16 | -366.7% | ✗ MISS |
Q4 2024 | Nov 4, 2024 | $-0.20 | $-0.23 | -15.0% | ✗ MISS |
Q3 2024 | Aug 6, 2024 | $-0.33 | $-0.28 | +15.2% | ✓ BEAT |
Q2 2024 | Apr 29, 2024 | $-0.33 | $-0.64 | -93.9% | ✗ MISS |
Q1 2024 | Mar 13, 2024 | $-0.22 | $-0.70 | -218.2% | ✗ MISS |
Q4 2023 | Nov 6, 2023 | $-0.36 | $-0.31 | +13.9% | ✓ BEAT |
Q3 2023 | Aug 3, 2023 | $-0.38 | $-0.14 | +63.2% | ✓ BEAT |
Q2 2023 | May 4, 2023 | $-0.30 | $-0.58 | -93.3% | ✗ MISS |
Q1 2023 | Mar 8, 2023 | $-0.75 | $-0.57 | +24.0% | ✓ BEAT |
Q4 2022 | Nov 3, 2022 | $-0.58 | $-0.63 | -8.6% | ✗ MISS |
Q3 2022 | Aug 4, 2022 | $-0.73 | $-0.42 | +42.5% | ✓ BEAT |
Q2 2022 | May 12, 2022 | $-0.62 | $-0.70 | -12.9% | ✗ MISS |
Q1 2022 | Mar 3, 2022 | $-1.05 | $-0.55 | +47.6% | ✓ BEAT |
Q4 2021 | Nov 4, 2021 | $-0.82 | $-0.82 | 0.0% | = MET |
Q3 2021 | Aug 5, 2021 | $-0.75 | $-0.88 | -17.3% | ✗ MISS |
Latest News
Cellectis shares are trading lower after arbitration ruled in favor of Allogene in relation to cemacabtagene ansegedleucel.
📉 NegativeBenzinga•Dec 16, 2025, 02:14 PM
Allogene Therapeutics Reports Result for Servier In Arbitration With Cellectis; Arbitration Ruling Reaffirms Allogene's Full Control of Cemacabtagene Ansegedleucel; Decision Reconfirms Allogene's Expanded Sub-License Covering EU And UK Rights with Options for Japan and China, Clearing the Path for Allogene to Acquire Full Global Rights
📈 PositiveBenzinga•Dec 15, 2025, 10:43 PM•Also:
Cellectis Shares Updated Eti-Cel Phase 1 Data At ASH 2025 In r/r NHL, With IL-2 Support Cohort Enrollment Starting Q1 2026
➖ NeutralBenzinga•Dec 8, 2025, 07:42 AM
Cellectis shares are trading higher after the company reported better-than-expected Q3 financial results.
📈 PositiveBenzinga•Nov 10, 2025, 02:28 PM
Cellectis Q3 Adj. EPS $0.02 Beats $(0.28) Estimate, Sales $37.164M Beat $6.900M Estimate
📈 PositiveBenzinga•Nov 7, 2025, 09:32 PM
Barclays Maintains Overweight on Cellectis, Raises Price Target to $8
📈 PositiveBenzinga•Oct 17, 2025, 01:22 PM•Also:
Frequently Asked Questions about CLLS
What is CLLS's current stock price?
Cellectis S.A. (CLLS) is currently trading at $4.37 per share. The stock has moved +5.05% today.
What is the analyst price target for CLLS?
The average analyst price target for CLLS is $6.00, based on 1 analyst.
What sector is Cellectis S.A. in?
Cellectis S.A. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is CLLS's market cap?
Cellectis S.A. has a market capitalization of $0.44 billion, making it a small-cap company.
Does CLLS pay dividends?
No, Cellectis S.A. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorACIU
AC Immune S.A.
$3.03
Mkt Cap: $0.3B
ALDX
Aldeyra Therapeutics, Inc.
$4.96
Mkt Cap: $0.3B
AMRN
Amarin Corporation plc
$13.80
Mkt Cap: $0.3B
ANRO
Alto Neuroscience, Inc.
$19.98
Mkt Cap: $0.6B
DBVT
DBV Technologies S.A.
$22.76
Mkt Cap: $0.5B
DRTS
Alpha Tau Medical Ltd.
$5.07
Mkt Cap: $0.4B
KRRO
Korro Bio, Inc.
$7.88
Mkt Cap: $0.1B
LRMR
Larimar Therapeutics, Inc.
$3.65
Mkt Cap: $0.3B
MREO
Mereo BioPharma Group plc
$2.00
Mkt Cap: $0.3B
SLN
Silence Therapeutics plc
$6.37
Mkt Cap: $0.3B
Explore stocks similar to CLLS for comparison